Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming Hou

Showing results (701-710 of 713) with videos related to

Pageof 72
Sort By:
Innovation (Cambridge (Mass.))|May 14, 2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III studyHuijuan Zhong, Shu Cheng, Xi Zhang, et al.
Platelets|July 3, 2020
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of agePeng Zhao, Ming Hou, Yi Liu, et al.
Haematologica|April 10, 2025
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized studyHuijuan Zhong, Shu Cheng, Jie Xiong, et al.
BMC Cancer|October 14, 2023
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trialZhongjun Xia, Yun Leng, Baijun Fang, et al.
Blood Advances|June 9, 2022
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter studyShan Chong, Peng Zhao, Rui-Bin Huang, et al.
International Journal of Hematology|April 6, 2018
Chinese guidelines for treatment of adult primary immune thrombocytopeniaXin-Guang Liu, Xiao-Chuan Bai, Fang-Ping Chen, et al.
JAMA|April 22, 2026
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical TrialPeng-Peng Xu, Yu-Qin Song, Jian-Zhen Shen, et al.
Journal of Hematology & Oncology|March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Bo Jia, Wei Xu, et al.
Advances in Therapy|March 22, 2021
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Hui Zhou, Huilai Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 26, 2021
Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)Li Chen, Hong-Ming Zhu, Yan Li, et al.
Pageof 72

Showing results (701-710 of 713) with videos related to

Sort By:
Pageof 72
Innovation (Cambridge (Mass.))|May 14, 2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III studyHuijuan Zhong, Shu Cheng, Xi Zhang, et al.
Platelets|July 3, 2020
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of agePeng Zhao, Ming Hou, Yi Liu, et al.
Haematologica|April 10, 2025
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized studyHuijuan Zhong, Shu Cheng, Jie Xiong, et al.
BMC Cancer|October 14, 2023
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trialZhongjun Xia, Yun Leng, Baijun Fang, et al.
Blood Advances|June 9, 2022
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter studyShan Chong, Peng Zhao, Rui-Bin Huang, et al.
International Journal of Hematology|April 6, 2018
Chinese guidelines for treatment of adult primary immune thrombocytopeniaXin-Guang Liu, Xiao-Chuan Bai, Fang-Ping Chen, et al.
JAMA|April 22, 2026
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical TrialPeng-Peng Xu, Yu-Qin Song, Jian-Zhen Shen, et al.
Journal of Hematology & Oncology|March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Bo Jia, Wei Xu, et al.
Advances in Therapy|March 22, 2021
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Hui Zhou, Huilai Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 26, 2021
Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)Li Chen, Hong-Ming Zhu, Yan Li, et al.
Pageof 72